Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1186.3000 -12.40 (-1.03%)
NSE Jan 12, 2026 10:53 AM
Volume: 142.8K
 

1186.30
-1.03%
Geojit BNP Paribas
with multiple regulatory milestones lined up in the coming quarters. Execution of the pipeline delivery and expansion initiatives is expected to support long-term value creation. Therefore, we maintain our rating on the stock at BUY, with rolledforward target price of Rs. 1,348, based on 17.5x FY27x Adj. EPS....
Number of FII/FPI investors decreased from 728 to 700 in Sep 2025 qtr
More from Aurobindo Pharma Ltd.
Recommended